Related Experiment Video
Updated: Dec 14, 2025
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
26.8K
GLP-1 receptor agonists for Parkinson's disease
Caroline A Mulvaney1, Gonçalo S Duarte2,3, Joel Handley1,4
1Lancaster Medical School, Lancaster University, Lancaster, UK.
The Cochrane Database of Systematic Reviews
|July 24, 2020
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists, like exenatide, may improve motor function in Parkinson's disease (PD). Evidence suggests a potential disease-modifying effect, though effects on quality of life remain unclear.
Area of Science:
- Neuroscience and Pharmacology
- Clinical Trials and Evidence Synthesis
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder impacting motor and non-motor functions.
- Insulin signaling, crucial for neuronal health, is impaired in PD.
- Glucagon-like peptide-1 (GLP-1) receptor agonists, used for type 2 diabetes, are being investigated for neuroprotective effects in PD.
Purpose of the Study:
- To evaluate the efficacy and safety of GLP-1 receptor agonists in treating Parkinson's disease.
- To synthesize current evidence on GLP-1 receptor agonist use for PD patients.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) comparing GLP-1 receptor agonists with placebo or conventional PD treatments.
- Searches conducted across major databases (Cochrane, MEDLINE, Embase) and clinical trial registries up to June 2020.
- Independent data extraction and risk of bias assessment by two reviewers, with evidence quality rated using GRADE.
Main Results:
- Two RCTs involving exenatide met inclusion criteria.
- Low-certainty evidence suggests exenatide improves motor impairment (MDS-UPDRS Part III) in PD patients, potentially exceeding the minimum clinically important difference.
- Evidence regarding exenatide's effect on health-related quality of life (HRQoL) and serious adverse events is inconclusive or very low-certainty.
Conclusions:
- Exenatide may offer benefits for motor symptoms in Parkinson's disease, with potential for a disease-modifying effect.
- The impact of exenatide on HRQoL and other non-motor outcomes requires further investigation.
- Ongoing research is exploring other GLP-1 receptor agonists for PD treatment.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
706
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
706
01:24Parkinson's Disease: Treatment
825
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
825
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:06Oral Hypoglycemic Agents: Glinides
478
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
478
01:23Dipeptidyl Peptidase 4 Inhibitors
446
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
446
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.0K